ClinicalTrials.gg
RecruitingNCT07723482Updated Oct 5, 2026

ML-016 in Advanced Cancer With Lung and/or Liver Involvement

A Phase 1/2 interventional study of ML-016 in Advanced Solid Tumor With Lung and/or Liver Involvement, sponsored by BrYet US, Inc.. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by BrYet US, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 5, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).

Read the detailed description

ML-016 will be administered intravenously as a monotherapy to assess safety, tolerability, pharmacokinetics (PK), and anti-tumor activity in participants with advanced/metastatic solid tumors with lung and/or liver involvement. The involvement of the lung and/or liver can involve primary or metastatic disease.

Participants eligible for treatment include those whose disease is refractory to standard therapeutic options or for which no standard measures with curative intent or likelihood of disease control are available, or such measures are not acceptable to the participant.

Participants will be administered ML-016 on Day 1 of each 21-day cycle. Treatment may continue until the participant's disease worsens or another treatment discontinuation criterion is met.

Phase 1 will be a standard dose escalation design, and Phase 2 will be a dose expansion design evaluating two doses in disease-specific cohorts.

02

Conditions studied

  • Advanced Solid Tumor With Lung and/or Liver Involvement

Browse trials for

Keywords

  • Solid Tumors
  • Refractory
  • Relapsed
  • Lung metastasis
  • Liver metastasis
  • Metastatic
  • Neoplasms
03

In context

Lead sponsor

This is the only study on the registry with BrYet US, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old on the day of signing the consent form
  2. Histopathological or cytological confirmed diagnosis of advanced (locally advanced or ) solid which is to standard therapeutic options or for which no standard measures with curative intent or likelihood of disease control are available, or such measures are not acceptable to the participant.
  3. Performance Status ≤1
  4. The participant has adequate baseline hematologic function, as demonstrated by the following:

    • ≥8.0 g/dL ,
    • ≥1.5 x 109/L,
    • ≥75 x 109/L
  5. The participant has adequate baseline kidney function, as demonstrated by the following:

    • Serum creatinine ≤1.5 x , and/or
    • Calculated ≥60 ml/min using the Cockroft-Gault formula or per institutional standard method
  6. The participant has adequate baseline liver function, as demonstrated by the following:

    • Total \<1.5 x ULN (except for participants with Gilbert syndrome), or
    • (AST)/alanine aminotransferase (ALT) ≤3 x ULN, or for participants with liver involvement AST/ALT \<5 x ULN
  7. using v 1.1 for solid tumors
  8. Evidence of tumor in the lung and/or liver based on imaging studies.
  9. For participants with lung metastases, adequate pulmonary function: , FVC and DLCO ≥50% predicted (corrected for hemoglobin) and no oxygen dependency.
  10. For participants with liver metastases, adequate liver function with less than 70% liver involvement as measured by imaging (i.e. CT, MRI, PET/CT, or ultrasound).
  11. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Documented to be surgically sterile or (amenorrhea 24 months and follicle-stimulating hormone [FSH] ≥30 mIU/mL), OR
    • Practicing true abstinence for at least 28 days prior to study treatment until 120 days after the last dose of study treatment and having a negative serum urine pregnancy test within 72 hours before initiating treatment, OR
    • Using 2 forms of highly effective , including 1 physical barrier (condom or diaphragm) plus another method, such as adequate hormonal method (eg, contraceptive implants, injectables, oral contraceptives) or nonhormonal methods (eg, intrauterine device, spermicidals) from screening or at least 28 days prior to study treatment administration (whichever is earlier) until 120 days after the last dose of study treatment and having a negative serum urine pregnancy test within 72 hours before initiating treatment.
  12. Male participants with female partners of may be enrolled if they are:

    • Documented to be surgically sterile (vasectomy), OR
    • Practicing true abstinence until 28 days after the last dose of study treatment, OR
    • Using 2 effective methods of contraception including one barrier method (e.g., condom with spermicide and contraception by female partner) for the duration of time on the study and for 120 days after administration of the last dose of study treatment, unless their partners are infertile or surgically sterile.
  13. Minimum of 3 months.
  14. Ability to read and understand the form and willingness and ability to give informed consent and demonstrate comprehension of the trial before undergoing any trial assessments.
  15. The participant can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
  16. The participant allows tissue to be available (archive or fresh tissue) unless approved by the Sponsor.

Exclusion criteria

Exclusion Criteria:

  1. Participants must not receive prior anticancer therapy or prior therapy within 3 weeks or 5 half-lives, whatever is shorter, or radiation therapy within 3 weeks, and must not undergo major surgery within 4 weeks prior to initiation of treatment on protocol. Palliative radiation therapy is allowed (no palliative radiation may be given to lesions).
  2. The participant must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 alopecia and/or neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible. Prior toxicities that resulted in laboratory abnormalities should have resolved to Grade ≤1 unless a higher-grade abnormality is allowed by the inclusion criteria. If medical therapy is required for the treatment of a laboratory abnormality, the dose and laboratory value(s) should be stable.
  3. Symptomatic or requiring treatment. Participants with treated brain metastasis must have stable disease for at least 4 weeks, as evidenced by brain imaging, and the participant must have been asymptomatic off for at least 2 weeks.
  4. Cardiac conditions: hypertension (BP > 160/100) despite optimal therapy, ventricular arrhythmias, significantly impaired cardiac function such as unstable angina pectoris, congestive heart failure with (NYHA) class III or IV, myocardial infarction within the 6 months prior to trial entry; signs of pericardial effusion, serious arrhythmia (including prolongation of >470 ms and/or pacemaker), or prior diagnosis of congenital long QT syndrome
  5. \<50% or below the lower limit of institutional normal (whichever is higher) on screening echocardiogram.
  6. History of anthracycline induced cardiotoxicity
  7. History of another primary (other than basal cell or squamous cell carcinoma, or in situ carcinoma) within 2 years prior to consent.
  8. Pregnancy or current breastfeeding or planning to breastfeed.
  9. Previous treatment with total cumulative doses of doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones (≥450 mg/m2).
  10. to doxorubicin, any of its , or other anthracyclines or anthracenediones or compounds of similar chemical or biologic composition as the study drug.
  11. The participant has a history of (non-infectious) pneumonitis or interstitial pulmonary disease that required corticosteroids within the past 3 months or has current pneumonitis or interstitial pulmonary disease.
  12. The participant has uncontrolled, pulmonary disease (e.g., , pulmonary hypertension) that in the opinion of the Investigator would put the participant at significant risk for pulmonary complications during the study.
  13. The participant has an active disease that required systemic treatment in the past. Participants who have not required systemic treatment for at least two years may be enrolled if permission is provided after discussion with the Medical Monitor (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic treatment, and is allowed).
  14. Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring intravenous antibiotics, severe malnutrition, chronic severe liver or renal disease).
  15. The participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    ML-016 Monotherapy

    ML-016 participants will be assigned to dose levels upon entry

    Drug: ML-016

Interventions

  • DrugML-016

    a pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle

    Also known as: iNPG-pDox

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) during the DLT assessment period

    The incidence of dose-limiting toxicities (DLTs) graded per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 during the DLT assessment period

    Time frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)

  2. Frequency and severity of adverse events (AEs) and serious AEs (SAEs)

    The frequency and severity of adverse events (AEs) and serious AEs (SAEs), treatment discontinuations due to toxicity, and clinical laboratory abnormalities

    Time frame: From first dose of study drug through 30 days following the last dose of study drug

  3. Maximum tolerated dose (MTD) and doses recommended for expansion

    Identify the MTD or maximum tested dose and doses recommended for expansion

    Time frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)

  4. Vital Signs: Blood Pressure

    Incidence and severity of changes in blood pressure from baseline

    Time frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug

  5. Vital Signs: Heart Rate

    Incidence and severity of changes in heart rate from baseline

    Time frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug

  6. Electrocardiograms (ECGs): QT Interval

    Incidence and severity of changes in ECG QT Interval from baseline

    Time frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug

  7. Echocardiograms (ECHO): LVEF

    Incidence and severity of changes in LVEF from baseline

    Time frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug

Secondary outcomes

  1. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the percentage of patients who have achieved complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.

    Time frame: At least 42 days after the first dose of investigational product

  2. Overall response rate (ORR)

    Overall response rate (ORR) is defined as the percentage of patients who have achieved CR or PR per RECIST 1.1.

    Time frame: From first dose of study drug through 12 months following first dose

  3. Duration of response (DOR)

    Duration of response (DOR) is defined as the time from the date measurement criteria are first met for patients who achieve PR or CR, to the date measurement criteria are first met for PD.

    Time frame: Time from the date measurement criteria are first met for patients who achieve PR or CR, to the date measurement criteria are first met for PD, assessed up to 12 months.

  4. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of initiation of study treatment to the date measurement criteria are first met for PD or death from any cause, whichever occurs first.

    Time frame: Time from the date of initiation of study treatment to the date measurement criteria are first met for PD or death from any cause, whichever occurs first, assessed up to 12 months.

  5. Time to Progression (TTP)

    Time to Progression (TTP) is defined as the time from the date of initiation of study treatment to the date that the measurement criteria are first met for PD.

    Time frame: Time from the date of initiation of study treatment to the date that the measurement criteria are first met for PD, assessed up to 12 months.

  6. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of initiation of study treatment to the date of death from any cause.

    Time frame: Time from the date of initiation of study treatment to the date of death from any cause, assessed up to 12 months.

  7. Pharmacokinetic Profile: Cmax

    Cmax: Maximum peak plasma concentration

    Time frame: From first dose of study drug through 21 days following the first dose of study treatment (1 cycle)

  8. Pharmacokinetic Profile: AUClast

    AUClast: Area under the concentration-time curve from Hour 0 through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn

    Time frame: From first dose of study drug through 21 days following the first dose of study treatment (1 cycle)

  9. Pharmacokinetic Profile: T½

    T½: Half-life

    Time frame: From first dose of study drug through 21 days following the first dose of study treatment (1 cycle)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 13 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Aug 2026 → Sep 2026, primary completion Aug 2027 → Oct 2027 and completion Aug 2030 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
Jul 23, 2026
StartActual
Sep 25, 2026was Aug 2026
Primary completionEst.
Oct 2027was Aug 2027
CompletionEst.
Oct 2030was Aug 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Southside Cancer Care Centre · Miranda, Australiano status→Recruiting
  • Illawarra Cancer Care Center, Wollongong Hospital · Wollongong, Australiano status→Not yet recruiting
  • Sunshine Coast Haematology and Oncology Clinic · Buderim, Australiano status→Recruiting
Oct 5, 2026
Start date
Aug 2026→Sep 25, 2026 (actual)
Oct 5, 2026
Primary completion
Aug 2027→Oct 2027
Oct 5, 2026
Study completion
Aug 2030→Oct 2030
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
    Show 3 sites
    • Southside Cancer Care Centre · Miranda, Australiano status→Recruiting
    • Illawarra Cancer Care Center, Wollongong Hospital · Wollongong, Australiano status→Not yet recruiting
    • Sunshine Coast Haematology and Oncology Clinic · Buderim, Australiano status→Recruiting
    Start date Aug 2026→Sep 25, 2026 (now actual)
    Primary completion Aug 2027→Oct 2027
    Study completion Aug 2030→Oct 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07723482
Lead sponsor
BrYet US, Inc.
Collaborators
Southern Star Research
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Sep 25, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Amanda Jubb, Clinical Project Manager, Southern Star Research
Contact
ajubb@southernstarresearch.com
+61 (0)2 9011 6266
Matt Wagener, VP Clinical Development Operations, BrYet
Contact
matt.wagener@bryetpharma.com
Brenton Seidl, MBBS, BSc, FRACP
principal investigator · Cancer Care Foundation Ltd, Sunshine Coast Haematology and Oncology Clinic
Apostolia Tsimberidou, MD, PhD, FASCO, FAAAS
study director · BrYet US, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion